PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8883586-6 1996 In other studies we determined the effect of increasing concentrations of ZDV on production of granulocyte colony-stimulating factor (G-CSF) protein [enzyme-linked immunosorbent assay (ELISA)] and mRNA by fetal and maternal monocytes, and on production of erythropoietin protein (ELISA) and mRNA by Hep3B cells. Zidovudine 74-77 colony stimulating factor 3 Homo sapiens 95-132 8883586-6 1996 In other studies we determined the effect of increasing concentrations of ZDV on production of granulocyte colony-stimulating factor (G-CSF) protein [enzyme-linked immunosorbent assay (ELISA)] and mRNA by fetal and maternal monocytes, and on production of erythropoietin protein (ELISA) and mRNA by Hep3B cells. Zidovudine 74-77 colony stimulating factor 3 Homo sapiens 134-139 8680517-7 1996 Exciting new management strategies appear to be the use of granulocyte colony-stimulating factor to enhance neutrophilia and zidovudine to reduce vertical transmission of HIV infection. Zidovudine 125-135 colony stimulating factor 3 Homo sapiens 59-96 1380256-9 1992 When erythropoietin was added to the regimen, combined G-CSF and EPO corrected both anemia and leukopenia and lessened subsequent zidovudine toxicity. Zidovudine 130-140 colony stimulating factor 3 Homo sapiens 55-60 7511543-5 1993 These results suggest that combined therapy with granulocyte colony-stimulating factor and erythropoietin may improve leukopenia and anaemia, which is not zidovudine-related, in children who have AIDS. Zidovudine 155-165 colony stimulating factor 3 Homo sapiens 49-86 1281810-9 1992 G-CSF plays an important role in the treatment of patients with HIV-associated Kaposi sarcoma and enables combined treatment with zidovudine, interferon, and cytostatic drugs. Zidovudine 130-140 colony stimulating factor 3 Homo sapiens 0-5 1279153-2 1992 We evaluated the effect of subcutaneously administered granulocyte colony-stimulating factor (G-CSF) in pediatric patients whose absolute neutrophil count was less than 0.8 x 10(9)/L during AZT therapy despite dosage reductions to 120 mg/m2 every 6 hours. Zidovudine 190-193 colony stimulating factor 3 Homo sapiens 94-99 1279153-9 1992 With doses of G-CSF ranging from 1 to 20 micrograms/kg per day, 17 of 19 patients were able to tolerate AZT at a dose of 120 to 180 mg/m2 every 6 hours. Zidovudine 104-107 colony stimulating factor 3 Homo sapiens 14-19 1279153-10 1992 We conclude that G-CSF therapy enables patients who have had AZT-related neutropenia to receive therapeutic doses of AZT. Zidovudine 61-64 colony stimulating factor 3 Homo sapiens 17-22 1279153-10 1992 We conclude that G-CSF therapy enables patients who have had AZT-related neutropenia to receive therapeutic doses of AZT. Zidovudine 117-120 colony stimulating factor 3 Homo sapiens 17-22 1720567-5 1991 The combination of G-CSF and recombinant human erythropoietin completely reversed the zidovudine-induced neutropenia of AIDS patients but was only partially effective in reversing anemia. Zidovudine 86-96 colony stimulating factor 3 Homo sapiens 19-24 1385275-0 1992 Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report. Zidovudine 76-86 colony stimulating factor 3 Homo sapiens 12-49 1385275-0 1992 Efficacy of granulocyte colony-stimulating factor (G-CSF) on neutropenia in zidovudine-treated patients with AIDS and ARC: a preliminary report. Zidovudine 76-86 colony stimulating factor 3 Homo sapiens 51-56 2022593-2 1991 Both G-CSF and GM-CSF have demonstrated the ability to correct leukopenia related to HIV infection and ameliorate the drug-related myelosuppressive effects of zidovudine, trimethoprim/sulfamethoxazole, ganciclovir, and, in the case of GM-CSF, alpha-interferon, and cancer chemotherapies. Zidovudine 159-169 colony stimulating factor 3 Homo sapiens 5-10 1714756-0 1991 Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. Zidovudine 84-94 colony stimulating factor 3 Homo sapiens 29-66 1714756-13 1991 We conclude that G-CSF increases the number of circulating neutrophilic granulocytes in zidovudine-treated patients at relatively low doses and with few side-effects. Zidovudine 88-98 colony stimulating factor 3 Homo sapiens 17-22 1709368-0 1991 Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Zidovudine 127-137 colony stimulating factor 3 Homo sapiens 34-71 2018046-3 1991 A combination of granulocyte colony-stimulating factor and erythropoietin has also been demonstrated to alleviate both neutropenia and anemia in patients with advanced AIDS or AIDS-related complex receiving zidovudine. Zidovudine 207-217 colony stimulating factor 3 Homo sapiens 17-54 1713806-11 1991 Combined G-CSF and EPO treatment corrected both anemia and leukopenia and reduced zidovudine toxicity. Zidovudine 82-92 colony stimulating factor 3 Homo sapiens 9-14